PTC Therapeutics announces plans for ataluren for Duchenne m

A new story now up on the website. For a while there we thought that ataluren was a failure, but after analysing and re-analysing the data they now believe that it does reduce the rate of deterioration of walking ability for boys with Duchenne muscular dystrophy (with a particular type of mutation). PTC Therapeutics say they are now in discussions with the regulatory authorities to work out the next steps to bring it to market.

http://www.muscular-dystrophy.org/research/news/2812_ptc_therapeutics_announces_plans_for_ataluren_for_duchenne_muscular_dystrophy

Kristina (Research Communications Officer, Muscular Dystrophy Campaign).